

Global Weight Loss Drugs Market:  
Analysis By Product Type (Powders and  
Pills, Liquids, and Injection), By Drug Type  
(Prescription Drugs and Over The Counter  
(OTC) Drugs), By Distribution Channel  
(Online and Offline), By Distribution  
Channel (Under 18 Years, 18-40 Years, 40-  
50 Years and Above 50 Years), By Region,  
Size and Trends with Impact of COVID-19  
and Forecast up to 2029

April 2024



# Global Weight Loss Drugs Market: Coverage

Executive Summary and Scope

Introduction/Market Overview

Global Market Analysis

Regional Market Analysis

Impact Of COVID-19

Dynamics

Competitive Landscape

Company Profiling

# Global Weight Loss Drugs Market: Coverage

## Scope of the Report

Attributes	Details
Title	Global Weight Loss Drugs Market: Analysis By Product Type (Powders and Pills, Liquids, and Injection), By Drug Type (Prescription Drugs and Over The Counter (OTC) Drugs), By Distribution Channel (Online and Offline), By Distribution Channel (Under 18 Years, 18-40 Years, 40-50 Years and Above 50 Years), By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029
Coverage	Global and Regional
Regional Coverage	North America, Europe, Asia Pacific, ROW
Market Influencing Variables	Growth Drivers, Challenges, Market Trends
Forecast Period of Market	2024-2029
Competition in the Market	Fragmented
Key Players	Merck KGaA, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Rhythm Pharmaceuticals Inc., Amgen Inc., Viking Therapeutics, Inc., Currax Pharmaceuticals LLC and VIVUS LLC

# Global Weight Loss Drugs Market

## Executive Summary

In an era marked by surging obesity rates and prevalent lifestyle-related illnesses, the quest for effective weight loss remedies has become increasingly urgent. Despite concerted efforts in diet and exercise, many individuals find conventional methods inadequate to achieve desired weight loss objectives. In such circumstances, weight loss medications emerge as a promising solution. These pharmaceutical interventions hold the potential to facilitate weight loss and improve overall health outcomes. The weight loss drugs market has experienced notable growth owing to the global rise in obesity rates, coupled with heightened awareness about health and fitness. Additionally, shifts in lifestyle, sedentary behaviors, and unhealthy dietary habits have fueled the need for effective weight management strategies, further propelling market growth. The global weight loss drugs market was valued at US\$3.83 billion in 2023, and is expected to be worth US\$44.12 billion in 2029.


Global weight loss drugs market can be classified on the basis of product type, drug type, distribution channel and end user. Injections are the fastest-growing segment in the weight loss drugs market, driven by their high efficiency and maximum bioavailability. Administered intravenously, they ensure rapid action, appealing to individuals with chronic obesity. Pharmaceutical firms are heavily investing in R&D to advance injection-based formulations, aiming to improve efficacy and patient adherence. The USFDA's recent approval of Wegovy (Semaglutide) injection for chronic weight management underscores the increasing emphasis on injection-based solutions to tackle the global obesity crisis. North America accounted for the maximum share in 2023.

The COVID-19 pandemic had several negative impacts on the weight loss drugs market, leading to a decline in market value. Lockdowns and social distancing measures implemented to curb the spread of the virus disrupted normal routines and limited access to healthcare facilities, reducing the number of consultations and prescriptions for weight management medications. Moreover, the pandemic exacerbated psychological stress, anxiety, and emotional eating behaviors among segments of the population, leading to weight gain and decreased motivation to pursue weight loss interventions.

Global weight loss drugs market is expected to show a significant increase during the forecasted period, i.e. from 2024 to 2029. The growth can be attributed to rising obesity rates, aging population, rising healthcare expenditure, increasing demand for effective weight management solutions, high prevalence of comorbidities like diabetes, sedentary lifestyle and increasing awareness. However, some challenges are also impeding the growth of the market such as stringent drug approval policies, availability of alternative treatment options, rebound effect and side effect of weight loss drugs.

# Weight Loss Drugs Market: Global Analysis

## Global Weight Loss Drugs Market by Value



Global weight loss drugs market was valued at US\$... billion in 2023 and is anticipated to reach up to US\$... billion by 2029 from US\$... billion in 2024, with a CAGR of xx%.


# Weight Loss Drugs Market: Global Analysis

Global Weight Loss Drugs Market by Product Type; 2023



Product Type	Share
Powders and Pills	xx%
Liquids	xx%
Injections	xx%


Global Weight Loss Drugs Market by Drug Type; 2023



Drug Type	Share
Prescription Drugs	xx%
Over The Counter (OTC) Drugs	xx%


# Weight Loss Drugs Market: Global Analysis

Global Weight Loss Drugs Market by End User; 2023



End User	Share
Under 18 Years	xx%
18-40 Years	xx%
40-50 Years	xx%
Above 50 Years	xx%



Global Weight Loss Drugs Market by Distribution Channel; 2023



Distribution Channel	Share
Offline	xx%
Online	xx%


# Weight Loss Drugs Market: Global Analysis

Global Weight Loss Drugs Market by Region; 2023




# Weight Loss Drugs Market: Product Type Analysis

## Global Weight Loss Powders and Pills Market by Value




## Global Weight Loss Liquids Market by Value




Product Type	CAGR (2024-2029)
Powders and Pills	xx%
Liquids	xx%
Injections	xx%

# Weight Loss Drugs Market: Drug Type Analysis

## Global Prescription Weight Loss Drugs Market by Value




## Global Over The Counter (OTC) Weight Loss Drugs Market by Value




Drug Type	CAGR (2024-2029)
Prescription Drugs	xx%
Over The Counter (OTC) Drugs	xx%

# Weight Loss Drugs Market: Distribution Channel Analysis

## Global Offline Weight Loss Drugs Market by Value




## Global Online Weight Loss Drugs Market by Value




Distribution Channel	CAGR (2024-2029)
Offline	xx%
Online	xx%

# Weight Loss Drugs Market: End User Analysis

## Global 18-40 Years Weight Loss Drugs Market by Value




## Global Above 50 Years Weight Loss Drugs Market by Value




End User	CAGR (2024-2029)
Under 18 Years	xx%
18-40 Years	xx%
40-50 Years	xx%
Above 50 Years	xx%

# Weight Loss Drugs Market: Regional Analysis

## North America Weight Loss Drugs Market by Value




## Europe Weight Loss Drugs Market by Value



Region	CAGR (2024-2029)
North America	xx%
Europe	xx%
Asia Pacific	xx%
ROW	xx%

# North America Weight Loss Drugs Market: An Analysis


North America Weight Loss Drugs Market by Region; 2023



Region	Share (2023)	CAGR (2024-2029)
The US	xx%	xx%
Canada	xx%	xx%
Mexico	xx%	xx%

# Europe Weight Loss Drugs Market: An Analysis


Europe Weight Loss Drugs Market by Region; 2023



Region	Share (2023)	CAGR (2024-2029)
Germany	xx%	xx%
France	xx%	xx%
UK	xx%	xx%
Rest of Europe	xx%	xx%

# Asia Pacific Weight Loss Drugs Market: An Analysis

Asia Pacific Weight Loss Drugs Market by Region; 2023



Region	Share (2023)	CAGR (2024-2029)
China	xx%	xx%
Japan	xx%	xx%
India	xx%	xx%
Rest of Asia Pacific	xx%	xx%

# Global Weight Loss Drugs Market: Dynamics



# Global Weight Loss Drugs Market: Competitive Landscape

## Players Profiled

- ❑ Merck KGaA
- ❑ GlaxoSmithKline Plc
- ❑ Eli Lilly and Company
- ❑ Boehringer Ingelheim
- ❑ Novo Nordisk A/S
- ❑ Rhythm Pharmaceuticals Inc.
- ❑ Amgen Inc.
- ❑ Viking Therapeutics, Inc.
- ❑ Currax Pharmaceuticals LLC
- ❑ VIVUS LLC